168 related articles for article (PubMed ID: 38226451)
21. The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy.
van Baal JOAM; Lok CAR; Jordanova ES; Horlings H; van Driel WJ; Amant FC; Van de Vijver KK
Virchows Arch; 2020 Oct; 477(4):535-544. PubMed ID: 32179982
[TBL] [Abstract][Full Text] [Related]
22. Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma.
Arend RC; Londoño AI; Montgomery AM; Smith HJ; Dobbin ZC; Katre AA; Martinez A; Yang ES; Alvarez RD; Huh WK; Bevis KS; Straughn JM; Estes JM; Novak L; Crossman DK; Cooper SJ; Landen CN; Leath CA
Mol Cancer Res; 2018 May; 16(5):813-824. PubMed ID: 29523763
[TBL] [Abstract][Full Text] [Related]
23. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
[TBL] [Abstract][Full Text] [Related]
24. Recombinant Human p53 Adenovirus Injection (rAd-p53) Combined with Chemotherapy for 4 Cases of High-grade Serous Ovarian Cancer.
Qu H; Xia Y; Li X
Curr Gene Ther; 2020; 20(4):313-320. PubMed ID: 32851960
[TBL] [Abstract][Full Text] [Related]
25. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
[TBL] [Abstract][Full Text] [Related]
26. Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors.
Yang SYC; Lheureux S; Karakasis K; Burnier JV; Bruce JP; Clouthier DL; Danesh A; Quevedo R; Dowar M; Hanna Y; Li T; Lu L; Xu W; Clarke BA; Ohashi PS; Shaw PA; Pugh TJ; Oza AM
Genome Med; 2018 Oct; 10(1):81. PubMed ID: 30382883
[TBL] [Abstract][Full Text] [Related]
27. Epithelial/mesenchymal heterogeneity of high-grade serous ovarian carcinoma samples correlates with miRNA let-7 levels and predicts tumor growth and metastasis.
Chirshev E; Hojo N; Bertucci A; Sanderman L; Nguyen A; Wang H; Suzuki T; Brito E; Martinez SR; Castañón C; Mirshahidi S; Vazquez ME; Wat P; Oberg KC; Ioffe YJ; Unternaehrer JJ
Mol Oncol; 2020 Nov; 14(11):2796-2813. PubMed ID: 32652647
[TBL] [Abstract][Full Text] [Related]
28. Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy.
Jiménez-Sánchez A; Cybulska P; Mager KL; Koplev S; Cast O; Couturier DL; Memon D; Selenica P; Nikolovski I; Mazaheri Y; Bykov Y; Geyer FC; Macintyre G; Gavarró LM; Drews RM; Gill MB; Papanastasiou AD; Sosa RE; Soslow RA; Walther T; Shen R; Chi DS; Park KJ; Hollmann T; Reis-Filho JS; Markowetz F; Beltrao P; Vargas HA; Zamarin D; Brenton JD; Snyder A; Weigelt B; Sala E; Miller ML
Nat Genet; 2020 Jun; 52(6):582-593. PubMed ID: 32483290
[TBL] [Abstract][Full Text] [Related]
29. Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study.
Dugo M; Devecchi A; De Cecco L; Cecchin E; Mezzanzanica D; Sensi M; Bagnoli M
Genes (Basel); 2019 Sep; 10(9):. PubMed ID: 31491988
[TBL] [Abstract][Full Text] [Related]
30. Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.
Gasimli K; Raab M; Tahmasbi Rad M; Kurunci-Csacsko E; Becker S; Strebhardt K; Sanhaji M
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142803
[TBL] [Abstract][Full Text] [Related]
31. A Comprehensive Analysis of Prognostic Indicators in Serous Ovarian Cancer Based on Leukocyte Migration and Immune Microenvironment.
Pan J; Chen X; Yang L; Song Y; Liu J; Li L; Lin Y; Tang L; Qiu S; Xu Q
Front Biosci (Landmark Ed); 2023 Jun; 28(6):130. PubMed ID: 37395023
[TBL] [Abstract][Full Text] [Related]
32. Distinct Transcriptional Programs in Ascitic and Solid Cancer Cells Induce Different Responses to Chemotherapy in High-Grade Serous Ovarian Cancer.
Loret N; Vandamme N; De Coninck J; Taminau J; De Clercq K; Blancke G; Jonckheere S; Goossens S; Lemeire K; De Prijck S; Verstaen K; Seurinck R; Van Dorpe J; Weyers S; Denys H; Van de Vijver K; Lambrecht BN; Tummers P; Saeys Y; Berx G
Mol Cancer Res; 2022 Oct; 20(10):1532-1547. PubMed ID: 35749080
[TBL] [Abstract][Full Text] [Related]
33. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
[TBL] [Abstract][Full Text] [Related]
34. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
[TBL] [Abstract][Full Text] [Related]
35. Cancer stem cells, epithelial-mesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma.
Chen X; Zhang J; Zhang Z; Li H; Cheng W; Liu J
Hum Pathol; 2013 Nov; 44(11):2373-84. PubMed ID: 23850493
[TBL] [Abstract][Full Text] [Related]
36. A chemotherapy response classifier based on support vector machines for high-grade serous ovarian carcinoma.
Sun CY; Su TF; Li N; Zhou B; Guo ES; Yang ZY; Liao J; Ding D; Xu Q; Lu H; Meng L; Wang SX; Zhou JF; Xing H; Weng DH; Ma D; Chen G
Oncotarget; 2016 Jan; 7(3):3245-54. PubMed ID: 26675546
[TBL] [Abstract][Full Text] [Related]
37. Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
Morden CR; Farrell AC; Sliwowski M; Lichtensztejn Z; Altman AD; Nachtigal MW; McManus KJ
Gynecol Oncol; 2021 Jun; 161(3):769-778. PubMed ID: 33714608
[TBL] [Abstract][Full Text] [Related]
38. Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma.
Reid BM; Vyas S; Chen Z; Chen A; Kanetsky PA; Permuth JB; Sellers TA; Saglam O
BMC Cancer; 2021 Jun; 21(1):714. PubMed ID: 34140011
[TBL] [Abstract][Full Text] [Related]
39. Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment.
Sriramkumar S; Metcalfe TX; Lai T; Zong X; Fang F; O'Hagan HM; Nephew KP
PLoS One; 2022; 17(8):e0271584. PubMed ID: 35921335
[TBL] [Abstract][Full Text] [Related]
40. Deciphering tumor immune microenvironment differences between high-grade serous and endometrioid ovarian cancer to investigate their potential in indicating immunotherapy response.
Yang H; Gu X; Fan R; Zhu Q; Zhong S; Wan X; Chen Q; Zhu L; Feng F
J Ovarian Res; 2023 Nov; 16(1):223. PubMed ID: 37993916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
